Lifa Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lifa Xu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Xiaochun Wang
Department of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, China
4 shared publications Zilun Shi
Department of Clinical Laboratory, Affiliated Cancer Hospital, Anhui University of Science and Technology, Huainan, 232001, China
4 shared publicationsJian Wang
Department of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan 232001, China
3 shared publicationsJianpeng Du
Department of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China
3 shared publicationsJingyan Zhang
Department of Clinical Laboratory, Affiliated Heping Hospital, Changzhi Medical College, Changzhi, 046000, China
3 shared publicationsJilei Ma
Department of Clinical Laboratory, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- 12 February 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (4) , 187
Comparison of long-term and short-term immunogenicity based on two different types of tuberculosis subunit vaccines
Tuberculosis (TB) remains the leading cause of death globally among infectious bacterial pathogens. As the only licensed vaccine for TB prevention, the BCG vaccine fails to deliver comprehensive protection. To address this limitation, this study selected Rv2031c (HspX)—a key antigen in the latent phase of TB—and Rv2428, an essential antigen in the active phase, for synthesis to construct the fusion antigen AH40. We adopted the pET − 28a vector for the expression of the fusion protein, while the pcDNA3.1(+) vector was utilized to construct the fusion gene DNA vaccine. Subsequently, the immunogenicity of the AH40 subunit vaccine and the corresponding DNA vaccine was evaluated and compared through experiments involving Mycobacterium tuberculosis (M.tb)—infected individuals and animal models.The fusion protein AH40 induced high levels of the cytokines IFN-γ, IL-2, and IL-6 in the peripheral blood of individuals infected with Mycobacterium tuberculosis (M.tb). Notably, the secretion levels of these cytokines stimulated by AH40 were higher than those induced by its individual antigen component. Consistent with this observation, AH40 exhibited enhanced immunogenicity compared to the single antigen. In mouse models, immunization with the protein-adjuvant vaccine AH40/Colloidal Manganese Adjuvant (AH40/MnJ) and the DNA vaccine AH40-DNA (AH40-D) both elicited high titers of IgG subclass antibodies. Further analysis revealed that the induced immune responses were biased toward a Th1-type profile. Collectively, these findings demonstrate that both vaccine formulations possess robust immunogenicity.
- 12 February 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (4) , 187
Comparison of long-term and short-term immunogenicity based on two different types of tuberculosis subunit vaccines
Tuberculosis (TB) remains the leading cause of death globally among infectious bacterial pathogens. As the only licensed vaccine for TB prevention, the BCG vaccine fails to deliver comprehensive protection. To address this limitation, this study selected Rv2031c (HspX)—a key antigen in the latent phase of TB—and Rv2428, an essential antigen in the active phase, for synthesis to construct the fusion antigen AH40. We adopted the pET − 28a vector for the expression of the fusion protein, while the pcDNA3.1(+) vector was utilized to construct the fusion gene DNA vaccine. Subsequently, the immunogenicity of the AH40 subunit vaccine and the corresponding DNA vaccine was evaluated and compared through experiments involving Mycobacterium tuberculosis (M.tb)—infected individuals and animal models.The fusion protein AH40 induced high levels of the cytokines IFN-γ, IL-2, and IL-6 in the peripheral blood of individuals infected with Mycobacterium tuberculosis (M.tb). Notably, the secretion levels of these cytokines stimulated by AH40 were higher than those induced by its individual antigen component. Consistent with this observation, AH40 exhibited enhanced immunogenicity compared to the single antigen. In mouse models, immunization with the protein-adjuvant vaccine AH40/Colloidal Manganese Adjuvant (AH40/MnJ) and the DNA vaccine AH40-DNA (AH40-D) both elicited high titers of IgG subclass antibodies. Further analysis revealed that the induced immune responses were biased toward a Th1-type profile. Collectively, these findings demonstrate that both vaccine formulations possess robust immunogenicity.
- 23 January 2024
- Published by Elsevier in Tuberculosis
- Vol. 145, 102480
Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants
- 23 January 2024
- Published by Elsevier in Tuberculosis
- Vol. 145, 102480
Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants
- 21 February 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (3) , 593-608
Long-Term Immunogenicity and In Vitro Prophylactic Protective Efficacy of M. tuberculosis Fusion Protein DR2 Combined with Liposomal Adjuvant DIMQ as a Boosting Vaccine for BCG
The resuscitation of dormant Mycobacterium tuberculosis is an important cause of adult tuberculosis (TB) transmission. According to the interaction mechanism between M. tuberculosis and the host, the latency antigen Rv0572c and region of difference 9 (RD9) antigen Rv3621c were selected in this study to prepare the fusion protein DR2. Stimulating clinically diagnosed active tuberculosis infections (i.e., TB patients), latent tuberculosis infections, and healthy controls confirmed that T lymphocytes could recognize DR2 protein in the peripheral blood of TB-infected individuals more than subcomponent protein. The DR2 protein was then emulsified in the liposome adjuvant dimethyl dioctadecyl ammonium bromide, and imiquimod (DIMQ) was administered to C57BL/6 mice immunized with Bacillus Calmette-Guérin (BCG) vaccine to evaluate their immunogenicity. Studies have shown that DR2/DIMQ, a booster vaccine for BCG primary immunization, can elicit robust CD4+ Th1 cell immune response and predominant IFN-γ+ CD4+ effector memory T cells (TEM) subsets. Furthermore, the serum antibody level and the expression of related cytokines increased significantly with the extension of immunization time, with IL2+, CD4+, or CD8+ central memory T cells (TCM) subsets predominant in the long term. This immunization strategy showed matched prophylactic protective efficacy by performing in vitro challenge experiment. This result provides robust evidence that the novel subunit vaccine prepared by fusion protein DR2 combined with liposomal adjuvant DIMQ is a promising TB vaccine candidate for further preclinical trials as a booster vaccine for BCG.
- 21 February 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (3) , 593-608
Long-Term Immunogenicity and In Vitro Prophylactic Protective Efficacy of M. tuberculosis Fusion Protein DR2 Combined with Liposomal Adjuvant DIMQ as a Boosting Vaccine for BCG
The resuscitation of dormant Mycobacterium tuberculosis is an important cause of adult tuberculosis (TB) transmission. According to the interaction mechanism between M. tuberculosis and the host, the latency antigen Rv0572c and region of difference 9 (RD9) antigen Rv3621c were selected in this study to prepare the fusion protein DR2. Stimulating clinically diagnosed active tuberculosis infections (i.e., TB patients), latent tuberculosis infections, and healthy controls confirmed that T lymphocytes could recognize DR2 protein in the peripheral blood of TB-infected individuals more than subcomponent protein. The DR2 protein was then emulsified in the liposome adjuvant dimethyl dioctadecyl ammonium bromide, and imiquimod (DIMQ) was administered to C57BL/6 mice immunized with Bacillus Calmette-Guérin (BCG) vaccine to evaluate their immunogenicity. Studies have shown that DR2/DIMQ, a booster vaccine for BCG primary immunization, can elicit robust CD4+ Th1 cell immune response and predominant IFN-γ+ CD4+ effector memory T cells (TEM) subsets. Furthermore, the serum antibody level and the expression of related cytokines increased significantly with the extension of immunization time, with IL2+, CD4+, or CD8+ central memory T cells (TCM) subsets predominant in the long term. This immunization strategy showed matched prophylactic protective efficacy by performing in vitro challenge experiment. This result provides robust evidence that the novel subunit vaccine prepared by fusion protein DR2 combined with liposomal adjuvant DIMQ is a promising TB vaccine candidate for further preclinical trials as a booster vaccine for BCG.
- 5 October 2022
- Published by Elsevier in Tuberculosis
- Vol. 137, 102270
Construction and expression of Mycobacterium tuberculosis fusion protein AR2 and its immunogenicity in combination with various adjuvants to form vaccine
- 5 October 2022
- Published by Elsevier in Tuberculosis
- Vol. 137, 102270
Construction and expression of Mycobacterium tuberculosis fusion protein AR2 and its immunogenicity in combination with various adjuvants to form vaccine
- 25 May 2022
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 41 (7) , 1039-1049
Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City
The dormancy survival regulator (DosR) antigens upgraded during latency and resuscitation-promoting factors (Rpfs) expressed over the reactivation from dormant Mycobacterium tuberculosis (M. tuberculosis) could be used to diagnose tuberculosis (TB) at different stages. We performed a retrospective cohort study based on four groups, including healthy controls (HCs), active tuberculosis infections (ATBs), latent tuberculosis infections (LTBIs), and relapse tuberculosis infections (RTBs) enrolled between November 2020 and June 2021. Compared to the fusion protein E6-C10, combined with early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate of 10 kDa (CFP-10), the DosR- or Rpf-encoded antigens could not elicit significant IFN-γ concentration for the diagnosis of ATB. Of note, the DosR antigens produce significantly more antigen-specific IFN-γ in LTBIs than Rpfs, and the levels of antigen-specific IFN-γ elicited in RTBs stimulated by Rpfs were higher than the DosR antigens. Among the DosR antigens, Rv2003c was the most immunogenic in diagnosing LTBIs, followed by Rv2007c and Rv2005c. As far as Rpfs are concerned, Rv0867c was the best antigen to identify RTBs, followed by Rv2389c and Rv1009. Both Rv2450c and Rv1884c showed relatively limited IFN-γ concentration in RTBs. Besides, the selected DosR antigens and Rpfs showed ideal specificity and inadequate sensitivity, which could have been enhanced by the fusion antigens prepared by the DosR antigens or Rpfs, respectively. The results of this study can provide more accurate detection methods for LTBIs and RTBs and could be used for screening the dormant M. tuberculosis throughout reactivation.
- 25 May 2022
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 41 (7) , 1039-1049
Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City
The dormancy survival regulator (DosR) antigens upgraded during latency and resuscitation-promoting factors (Rpfs) expressed over the reactivation from dormant Mycobacterium tuberculosis (M. tuberculosis) could be used to diagnose tuberculosis (TB) at different stages. We performed a retrospective cohort study based on four groups, including healthy controls (HCs), active tuberculosis infections (ATBs), latent tuberculosis infections (LTBIs), and relapse tuberculosis infections (RTBs) enrolled between November 2020 and June 2021. Compared to the fusion protein E6-C10, combined with early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate of 10 kDa (CFP-10), the DosR- or Rpf-encoded antigens could not elicit significant IFN-γ concentration for the diagnosis of ATB. Of note, the DosR antigens produce significantly more antigen-specific IFN-γ in LTBIs than Rpfs, and the levels of antigen-specific IFN-γ elicited in RTBs stimulated by Rpfs were higher than the DosR antigens. Among the DosR antigens, Rv2003c was the most immunogenic in diagnosing LTBIs, followed by Rv2007c and Rv2005c. As far as Rpfs are concerned, Rv0867c was the best antigen to identify RTBs, followed by Rv2389c and Rv1009. Both Rv2450c and Rv1884c showed relatively limited IFN-γ concentration in RTBs. Besides, the selected DosR antigens and Rpfs showed ideal specificity and inadequate sensitivity, which could have been enhanced by the fusion antigens prepared by the DosR antigens or Rpfs, respectively. The results of this study can provide more accurate detection methods for LTBIs and RTBs and could be used for screening the dormant M. tuberculosis throughout reactivation.
- 26 February 2022
- Published by Elsevier in Tuberculosis
- Vol. 134, 102186
Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster
- 26 February 2022
- Published by Elsevier in Tuberculosis
- Vol. 134, 102186
Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster
- 6 December 2013
- Published by Springer Nature
- p. 501-509
Reformation and Application of “Project-Tutor System” in Experimental Course Teaching of Fundamental Medicine
- 6 December 2013
- Published by Springer Nature
- p. 501-509
Reformation and Application of “Project-Tutor System” in Experimental Course Teaching of Fundamental Medicine